Table 6 Gender distribution of the patients from which the various samples were obtained
From: Pan-cancer analysis of TCGA data reveals notable signaling pathways
Cancer | Tumor samples | Non-tumor samples | ||
|---|---|---|---|---|
| Â | Female | Male | Female | Male |
Breast cancer | 461 | 5 | 60 | 1 |
Colon adenocarcinoma | 67 | 76 | 14 | 5 |
Glioblastoma | 219 | 348 | 5 | 5 |
Kidney renal papillary cell carcinoma | 4 | 12 | 0 | 0 |
Low grade glioma | 9 | 18 | 0 | 0 |
Lung adenocarcinoma | 18 | 14 | 0 | 0 |
Lung squamous cell carcinoma | 44 | 110 | 00 | 0 |
Ovarian carcinoma | 572 | 0 | 8 | 0 |
Rectum adenocarcinoma | 31 | 38 | 3 | 0 |
Uterine corpus endometriod carcinoma | 54 | 0 | 0 | 0 |
Pan-cancer (total) | 1479 | 621 | 90 | 11 |